Cargando…

Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey

INTRODUCTION: Sleep disorders are the third most common indication for the prescription of medical cannabis products in Australia, after pain and anxiety. While the use of cannabis for medical purposes is growing in Australia, underlying consumer behaviours and patterns of use, particularly around s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suraev, Anastasia, Mills, Llewellyn, Abelev, Sarah V, Arkell, Thomas R, Lintzeris, Nicholas, McGregor, Iain S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120832/ https://www.ncbi.nlm.nih.gov/pubmed/37090897 http://dx.doi.org/10.2147/NSS.S390583

Ejemplares similares

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey
por: Arkell, Thomas R., et al.
Publicado: (2023)

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
por: Lintzeris, Nicholas, et al.
Publicado: (2020)

The “Next Day” Effects of Cannabis Use: A Systematic Review
por: McCartney, Danielle, et al.
Publicado: (2023)

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey
por: Karanges, Emily A, et al.
Publicado: (2018)

Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients
por: Benson, Melissa J, et al.
Publicado: (2020)

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials
por: Arkell, Thomas R., et al.
Publicado: (2021)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Detection of Δ(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
por: Arkell, Thomas R., et al.
Publicado: (2019)

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
por: Mills, Llewellyn, et al.
Publicado: (2022)

Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile
por: Swift, Wendy, et al.
Publicado: (2013)

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease
por: Benson, Melissa J, et al.
Publicado: (2020)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years
por: MacPhail, Sara L., et al.
Publicado: (2022)

Prescribing medicinal cannabis
por: Arnold, Jonathon C, et al.
Publicado: (2020)

Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research
por: McCartney, Danielle, et al.
Publicado: (2020)

Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 survey
por: Bawa, Zeeta, et al.
Publicado: (2022)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
por: Jackson, Melissa A., et al.
Publicado: (2021)

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
por: Arunogiri, Shalini, et al.
Publicado: (2021)

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Opioid prescribing in Australia: too much and not enough
por: Dunlop, Adrian J, et al.
Publicado: (2021)

Orally administered cannabidiol does not produce false‐positive tests for Δ(9)‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
por: McCartney, Danielle, et al.
Publicado: (2021)

A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis
por: Bawa, Zeeta, et al.
Publicado: (2022)

Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022)

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)
por: Mersiades, Antony J, et al.
Publicado: (2018)

Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial
por: Lavender, Isobel, et al.
Publicado: (2023)

Assessment of Medical Cannabis and Health-Related Quality of Life
por: Arkell, Thomas R., et al.
Publicado: (2023)

Cannabis Users' Recommended Warnings for Packages of Legally Sold Cannabis: An Australia-Centered Study
por: Malouff, John M., et al.
Publicado: (2016)

Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
por: Cairns, Elizabeth A., et al.
Publicado: (2023)

Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ(9)-THC at Human CB(1) and CB(2) Receptors
por: Santiago, Marina, et al.
Publicado: (2019)

Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019
por: Black, Emma, et al.
Publicado: (2022)

Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
por: Heblinski, Marika, et al.
Publicado: (2020)

20. Integrating Cannabis Into Clinical Care
por: Abrams, Donald
Publicado: (2013)

Navigating the grey: Experiences of incremental cannabis reform in Australia
por: Barrett, Liz, et al.
Publicado: (2022)

The Rise and Rise of Medicinal Cannabis, What Now? Medicinal Cannabis Prescribing in Australia 2017–2022
por: Hallinan, Christine Mary, et al.
Publicado: (2022)

A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function
por: Milligan, Carol J., et al.
Publicado: (2022)

Trends in cannabis use intention around the period of cannabis legalisation in Australia: An age‐period‐cohort model
por: Chiu, Vivian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgs00fi20m11s8m3d23hqenaso